Liraglutide Treatment to Patients With Severe Renal Insufficiency

NCT01394341 on ClinicalTrials.gov · last registry update 2013-10-09

Finished October 2013, after enrolling 40 people. Primary outcome, as filed: Plasma liraglutide concentration (pmol/L). liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Bo Feldt-Rasmussen
Sponsor type: Other
Enrollment: 40
Started: 2011-09
Primary completion: 2013-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Plasma liraglutide concentration (pmol/L)

Conditions studied

Type 2 Diabetes Mellitus · End-stage Renal Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.